Stay updated on Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedRevision number updated from v3.6.2 to v3.6.3, indicating a small software/formatting update rather than a change to the study details or user-facing content. No substantive content changes are indicated.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision label updated from v3.6.0 to v3.6.2. This reflects a system/template update, and no study details or related content seem to be affected.SummaryDifference0.0%

- Check34 days agoChange DetectedUpdates to the study record page include the addition of key attribution details (Craig L Slingluff, Jr and University of Virginia) and new navigation/help links (How to Read a Study Record, Common Questions, How to Join a Study). It also shows changes to status verification labels (Last verified, Last known status was) and a new revision tag (Revision: v3.6.0).SummaryDifference1%

- Check41 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, signaling a small update to the page. The change appears to be a version bump without visible content edits.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision label updated from v3.5.3 to v3.5.4, representing a newer version of the page. It is a metadata/version update and does not reflect a substantive change to study content.SummaryDifference0.1%

- Check83 days agoChange DetectedUpdates the ClinicalTrials.gov page “Revision” from v3.5.2 to v3.5.3, reflecting a platform/version release rather than any change to the underlying study record.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.